Biogen secured its first global approval in China for felzartamab, approving the monoclonal antibody for treatment of second-line multiple myeloma alongside lenalidomide and dexamethasone. The approval expands Biogen’s presence in a competitive myeloma market and adds another immune-targeted option to combination regimens in later lines.